Australia-listed biotech Bionomics has seen Merck expand its interest in a broad pipeline of candidates, buying nearly 5.3% of its outstanding ordinary shares at a 29% premium along with an additional $9 million investment.
Indian drug giant Cipla and vaccinemaker Serum have partnered for a third time to provide vaccines, this time for Serum's operations in South Africa. Cipla and Serum previously worked together on vaccines in Europe and then to provide flu vaccines in India, according to a report in The Hindu newspaper.
WuXi PharmaTech, working to expand the adoption of its new clinical genomics service, partnered up with a large Qatari hospital to sequence the genomes of patients and help guide treatment.
Preclinical CRO Charles River Laboratories brought in three new discovery contracts with outfits funded by the Wellcome Trust, lending its expertise in early-stage drug development.
German drug developer Evotec signed a 5-year, $4.9 million agreement with the National Cancer Institute to help the group build and manage its library of potential oncology drugs.
China Biologic Products said its subsidiary, Guizhou Taibang Biological Products, has signed a deal with Xinjiang Deyuan Bioengineering to source 500 tons of raw plasma over the next three years, the company said in a news release.
Japan's SymBio will develop and commercialize pain medicine Ionsys in an exclusive licensing deal with the U.S.-based Medicines Co., marking its first product in the Japanese market and a company push to expand abroad.
French drugmaker Servier has outlicensed some early-stage cancer treatments to Horizon Discovery, holding on to the rights to buy them back if they come through in preclinical development.
Specialty pharma OptiNose hopes to use up to $30 million in new financing to get its OPN-375 in combination with its novel breath-powered device through the FDA. But the agency already demonstrated some skepticism around the device last year--it issued a complete response letter to OptiNose partner Avanir because of device errors and required further testing.
Venture-backed Ark Biosciences has successfully completed a Phase I clinical trial of work on anti-respiratory syncytial virus (RSV) candidate AK0529, hitting a key milestone for the respiratory viral infection and viral hepatitis focused company.